Skin care company Crown Aesthetics reported on Wednesday the receipt of Medical Device Single Audit Programme (MDSAP) certification upon a rigorous audit by BSI (British Standards Institute).
Following MDSAP certification, the company will continue selling SkinPen, the first FDA cleared microneedling device, in Canada, Australia, Brazil and Japan.
MDSAP allows a single regulatory audit of a medical device manufacturer's quality management system to satisfy the requirements of multiple regulatory authorities. It covers the requirements of ISO 13485:2016 plus Good Manufacturing Practices (GMP) for each applicable regulatory authority. MDSAP is validation of the company's world-class service and pursuit of quality, safety and efficiency.
Emmaus Life Sciences' Endari label enhancements receive US FDA approval
Accord Healthcare introduces Dehydrated Alcohol Injection for cardiovascular indications
CARsgen Therapeutics' satri-cel NDA accepted by Chinese regulator
Sanofi receives FDA orphan drug designation for riliprubart in transplant rejection
Hoth Therapeutics reports positive interim results for HT-001 topical therapy
Breckenridge Pharmaceutical's generic for Ablysinol granted final FDA approval
Hemab Therapeutics presents bleeding disorder clinical and preclinical data at ISTH 2025 Congress
Cumberland Pharmaceuticals reports ifetroban Phase 2 DMD heart disease trial results
Sarclisa recommended for EU approval in newly diagnosed transplant-eligible multiple myeloma